RGEN

Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2004

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2004, for Repligen Corporation, a biotechnology company developing therapeutic products for neuropsychiatric and autoimmune disorders. The company operates as a single segment, generating revenue primarily from the sale of rProtein A products for antibody purification and SecreFlo for gastroenterology. Repligen funds its development-stage therapeutic candidates (including secretin and uridine) through product sales and equity financing.

Key Financial Metrics

Liquidity: Total cash and marketable securities stood at approximately $24.9 million. The company reported a net cash inflow from operating activities of $41,906, a significant improvement from a $1.35 million outflow in the prior year.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 36% year-over-year, driven by a 39% increase in rProtein A sales ($2.24M vs. $1.61M) and a 32% increase in SecreFlo sales ($572k vs. $434k).
• Expense Reduction: Total operating expenses decreased 27% to $2.42 million. Selling, general, and administrative (SG&A) expenses dropped 46% primarily due to the absence of litigation costs associated with the ProNeuron trial and reduced marketing expenses compared to the prior year.
• Profitability: The net loss narrowed significantly to $645,086 from $2.03 million in the prior year, reflecting both revenue growth and cost containment.
• Inventory Management: Inventory levels decreased by $242,533, contributing to positive cash flow from operations.

Outlook, Risks, and Contingencies

Management Commentary: Management expects to continue incurring operating losses for the foreseeable future as it invests in R&D. Future capital requirements include clinical trials, equipment purchases, and intellectual property protection. The company relies on product sales to fund development, aiming to minimize operating losses.

Legal Proceedings & Contingencies:

• ChiRhoClin, Inc. (SecreFlo Supplier): Repligen terminated its licensing agreement with its sole SecreFlo supplier in February 2004 for breach of contract. Repligen seeks to recover approximately $5 million in payments. An arbitration hearing is scheduled for March 2005. If the supplier fails to provide product, revenues could be negatively impacted.
• Bristol-Myers Squibb: Repligen lost an appeal regarding inventorship of CTLA4-Ig patents. The Federal Circuit affirmed the lower court's ruling in favor of Bristol-Myers Squibb, which may restrict Repligen's ability to commercialize CTLA4-Ig.
• ImClone Systems: Repligen and MIT filed a patent infringement lawsuit against ImClone regarding the drug Erbitux, seeking damages for the use of patented genetic elements.

Market Risk: The company holds significant marketable securities. A hypothetical 100 basis point increase in interest rates would decrease the fair value of these investments by approximately $142,000.

Investor Verification Checklist

• Supplier Dependency: Verify the status of the arbitration with ChiRhoClin and the certainty of future SecreFlo supply, given the termination of the licensing agreement.
• Customer Concentration: Note that two customers accounted for approximately 70% of revenue in Q2 2004 (50% and 20% respectively).
• Patent Litigation Outcomes: Monitor the ImClone lawsuit for potential revenue upside and the impact of the Bristol-Myers Squibb loss on the CTLA4-Ig pipeline.
• Cash Burn Rate: Assess the sufficiency of the $24.9 million cash position to fund ongoing R&D and legal costs without immediate equity dilution.
• Revenue Volatility: Acknowledge that rProtein A revenues are subject to significant quarterly fluctuations based on large-scale production orders.